Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb81bf5f72f9efb30a9d6ea95dd7300a |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
filingDate |
2007-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2013-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a049e6a9465d94098ad01f122a5ba2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86be7bf4e28267a3d5b2789eb25e161b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a2347962abf4ce4f2eb2da03265065f |
publicationDate |
2013-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2007220515-B2 |
titleOfInvention |
Screening for anti-cancer compounds using netrin-1 activity |
abstract |
The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells. |
priorityDate |
2006-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |